key: cord-0036163-1dihde3a authors: Kuechler, Ernst; Seipelt, Joachim title: Inhibitors of respiratory viruses date: 2006 journal: New Concepts of Antiviral Therapy DOI: 10.1007/978-0-387-31047-3_4 sha: f1473f0ab34b7df80b30d91e695e0d10899a317c doc_id: 36163 cord_uid: 1dihde3a nan There are many viruses which cause diseases in the respiratory tract of humans and mammals. A variety of different virus families such as rhinovirus, influenza virus, parainfluenza virus, respiratory syncytial virus (RSV), coronaviruses and adenovirus are responsible for more than 95% of all human respiratory infections. The remaining 5% are due to bacterial infections. Typical symptoms of respiratory infections develop one to two days after viral inoculation and include nasal discharge, sneezing, sore throat, cough, headache and general weakness. In severity, the symptoms may vary from a mild "common cold" to a severe influenza virus infection, but they still make some 60 million people seek medical advice every year in the United States alone (Bertino 2002) . The National Centre for Health Statistics estimated that in 1996 about 62 million cases of viral respiratory tract infections (VRTI) required medical attention or resulted in restricted activity in the United States. Roughly one in six respiratory infections leads to a doctor's office visit and up to 50% of these visits result in an antibiotic prescription, which mainly treats secondary infections but fails to tackle the respiratory tract infections is illustrated by the fact that in 1998 more antibiotic prescriptions were written for presumed VRTIs than for bacterial The need for an effective treatment of VRTIs is obvious. In 1998, people in the United States spent around $ 5 billion on over-the-counter products that relieve symptoms of the common cold. This corresponds to a rise by more than 50% as compared to 1995, when the amount spent was $ 3.3 billion. As viral respiratory infections are caused by a wide range of different viruses that require an equally great variety of treatments, establishing successful causative treatment is a challenging task. We will provide an overview on treatment approaches and discuss problems and potential solutions for successful therapy. Viral respiratory tract infections are caused by a heterogeneous group of viruses of different genera. The relative proportions of these viruses vary and depend on several factors such as season, age but also viral sampling and detection technique. About 30-50% of all infections -generally termed as "common cold" -are caused by rhinoviruses of the picornavirus group. This makes common cold the most widespread acute disease in individuals viral respiratory infections are caused by influenza virus, which makes them more severe and sometimes lethal. Most people recover from the illness; however, the Centers for Disease Control and Prevention (CDC) estimates that in the United States an average of 36,000 persons die from influenza and its complications every year, most of them elderly people. Respiratory syncytial virus (RSV) is the main cause of infant bronchiolitis and pneumonia. The virus is ubiquitous, highly infectious and reaches epidemic proportions every year during the winter months. In the total population, primary viral infection (Bertino, 2002) . The market value relating to infections, at a cost of approximately $ 726 million (Gonzales et al. , 2001) . (Monto et al. , 1993 (Monto et al. , , 2002a Makela et al., 1998) . Approximately 5-15% of all approximately 5% of all VRTI cases are caused by RSV. Parainfluenza virus can cause upper and lower respiratory tract infections in both adults and children (3%). Coronaviruses are found in 7-18% of all adults suffering from that human coronaviruses account for up to 35% of cases of upper respiratory illness. While it is clear that human coronavirus can play an important role in respiratory outbreaks a much lower frequency is found in families, i.e. adenovirus and enterovirus, account for minor shares of respiratory infections. The fact that up to 30% of VRTIs are not assigned to a certain virus species is probably due to suboptimal sampling and detection An analysis of available epidemiology data has shown a distinct and consistent seasonal pattern in the occurrence of respiratory viruses (Monto 2002a) . In temperate regions of the northern hemisphere, rhinoviruses account for up to 80% of all viruses circulating in early autumn (Arruda spring is an even more dangerous time for rhinovirus transmission. Although overall rates of respiratory diseases are lower in summer, rhinoviruses are the type of virus that is most frequently isolated at that time of the year. In winter, other viral agents, among them influenza viruses, parainfluenza virus and respiratory syncytial virus, predominate in the northern hemisphere (Monto 2002b) . methods in some cases (Heikkinen et al. , 2003) . and Gwaltney et al. , 1966) . VRTIs (Larson et al. , 1980; Nicholson et al. , 1997) . Single study estimated most studies (Vabret et al. , 2003; Louie et al. , 2005) . The two remaining virus Makela et al., 1998) . In some years and some geographic areas, From a clinical point of view, ascertaining upper respiratory tract virus infection is difficult, because many respiratory viruses cause similar symptoms. Temperatures above 37.8°C in the initial stage of the disease indicate influenza rather than other virus infections. Early identification of respiratory viruses is essential for effective diagnosis and patient management, as only for influenza virus causative treatment is available. Methods for identifying viruses include viral culture, antigen detection and highly sensitive molecular biology techniques based on polymerase chain reaction (PCR). Isolating viruses in cell culture is considered the gold standard but of limited relevance in clinical practice because it is too slow. Several antigen detection tests are available for diagnosing influenza A and 2002). Due to the high number of human rhinovirus (HRV) serotypes, detecting these viruses by immunological methods is not easy although PCR methods are available. A main disadvantage of the latter is the fact that they do not discriminate between infective viruses but rather detect the viral genome. Currently, we lack a general treatment that addresses the underlying causes of viral respiratory tract infections, i.e. the virus infection. In principle, antiviral drugs can be designed to either target a viral or a cellular protein. Targeting specific proteins of viruses basically has the advantage of being less toxic for cells with a narrow antiviral spectrum, while targeting cellular molecules might yield compounds with a broader antiviral activity. In the first case, the likelihood of generating druginsensitive mutants is high, while this risk is unlikely in the latter case. The concept was proved for both strategies, e.g. in infections with human rhinoviruses. One example is the successful use of inhibitors targeting the viral proteinase 3C in HRV. A cellular approach was taken by the use of interferon to stimulate cellular defense against rhinovirus. For a thorough review of the development of antiviral strategies see a recent review by DeClerq (2004) . B, parainfluenza, RSV and adenoviruses (Kim et al. 1983; Waris et al., 1988; Nikkari et al. , 1989 ) though they are not widely used (Steininger et al. , 2001, Rhinovirus infections may account for up to one third of all "common colds". The virus family consists of more than 100 serotypes, is ubiquitous and can cause repeated episodes of infection throughout an individual's life time. Infection in otherwise healthy persons is unpleasant though usually self-limited. However, certain populations may be predisposed to severe manifestations, including bronchiolitis and pneumonia in infants and exacerbations of pre-existing airway disease in persons with chronic obstructive lung disease, asthma and cystic fibrosis (Hayden 2004 ). The pathogenesis of a rhinovirus infection was elucidated by many 1977, 1978) . Infection begins with the deposition of viral particles in the anterior nasal mucosa or in the eye, from where the virus can be transported to the nose via the lacrimal duct. At the mucosal surface, virions attach themselves to cellular receptors. Based on receptor specificity, rhinoviruses can be divided into two groups: the viruses belonging to the "major group" attach themselves to the cellular adhesion molecule-1 (ICAM-1), whereas "minor group" viruses bind to the LDL receptor or LDL-related proteins internalization and uncoating, the viral plus-strand RNA is translated into one large polyprotein, which is proteolytically processed by two viral proteases -2A and 3C -into the individual viral proteins. Replication is mediated via a minus-strand RNA intermediate and catalyzed by the viral 3D polymerase. Resulting RNA molecules can then be used for translating viral proteins or are packaged into viral particles in a late phase of the infection. Viral proteinases specifically cleaving factors such as the eukaryotic initiation factor 4G required for cellular cap-dependent translation turn the host cell into a virus producing machine (host cell shutoff) (Etchison et al. involving direct binding of ribosomal subunits to internal ribosomal entry sites, which facilitates virus production. In addition, this host cell shutoff limits the defense response to the viral infection e.g., the interferon response, mediated via destruction of the host cell. Surprisingly and differently to patients infected with influenza virus, individuals infected with rhinoviruses show no major tissue destruction in nasal biopsies. This observation suggests that the clinical symptoms of rhinovirus infection might not be due to cell bind to heparan sulfate proteoglycan (Vlasak et al. , 2005) . Following as cellular translation is inhibited (Weber et al. , 2004) . Viral release is , 1987). The viral mRNA is translated via a cap-independent mechanism studies of volunteers infected with rhinoviruses (Gwaltney et al., 1966 , 1975 , (Greve et al. , 1989 Hofer et al. , 1994) . The serotype HRV 89 is reported to destruction mediated by virus replication (cytopathic effect) but are primarily caused by the immune response of the host. Several inflammatory mediators can be found in the nasal secretion of patients with common cold, e.g. interleukin 1, 6 and 8, histamines, leukotriens and kinins. Interleukin 6 and 8 levels correlate with the severity of symptoms. In contrast to the proinflammatory reaction, rhinovirus can even down-modulate an appropriate immune responses by inducing immunosuppressive cytokine interleukin immunological host response to rhinovirus infection is far from being fully explored. On average, colds take one week, although 25% of all cases last longer. Viral shedding can be observed up to three weeks, though the risk of With the help of modern PCR techniques, rhinoviruses have been detected more frequently at sites distant from the primary infection. This led to a greater appreciation of the role this pathogen plays in upper and lower respiratory tract disease. Specifically, rhinoviruses are supposed to be exacerbations, chronic obstructive pulmonary diseases and lower respiratory infections in elderly, neonates and in immunocompromised individuals (Greenberg 2003) . In children, the most common bacterial complication is otitis media, which can occur in up to 20% of all children with viral upper respiratory tract infections. Using PCR techniques, various viruses were detected in middle ear fluid, suggesting a causative involvement of these 2005). Even though the common cold and its complications are medically important, efforts to find causative treatment have been rather futile. At present, there are no approved antiviral agents for treating HRV infection. Several treatment strategies were evaluated, albeit with limited success so far. 1999). However, the transmission diminishes after three days (D Alessio et al. , 1976) . , 10 as was shown in monocytes (Stockl et al. , associated with otitis media (Pitkaranta et al. , 1998 (Pitkaranta et al. , , 1999 , sinusitis, asthma viruses (Pitkaranta et al. , , 1998 (Pitkaranta et al. , , 1999 (Pitkaranta et al. , , 2002 . HRVs were also detected in the lower respiratory tract (Papadopoulos et al. , 1999; Mosser et al. , 2002, Figure 2 . Rhinovirus life cycle. Current appr oaches for viral inhibition ar e indicated. In the seventies of the last century Isaacs and Lindenmann reported a factor that could induce a virus resistant state that was termed "interferon" an antiviral response in the host cell based on activation of expression of more than 300 interferon induced genes that have antiviral, antiproliferative or immunomodulatory functions. The best studied interferon induced antiviral proteins are the 2'5' oligo adenylate synthetase, protein kinase R and the MX GTPases. From experiments in knock-out mice it became importance of the interferon response to viral infections is clear, their mode broad induction of a cellular antiviral response inter-feron were used as "general" antiviral medication. In several studies, it proved to be an effective treatment with interferon neither cured experimentally induced nor naturally a cellular rather than a viral function. Sperber et al. , 1989) . Interferons are an example of molecules targeting (Isaacs et al. , 1957a (Isaacs et al. , , 1957b Lindenmann et al. , 1957) . Interferon can trigger evident that also additional pathways exist (Zhou et al. , 1999) . Although the of action is still incompletely understood (Weber et al. , 2004) . Based on the histo occurring colds (Farr et al. ,1984; Hayden et al. , 1984 Hayden et al. , , 1988b pathological signs of nasal irritation (Hayden et al. , 1986) . However, prophylactic but was associated with significant clinical and -As the majority of HRVs bind to the intercellular adhesion molecule-1 (ICAM-1) as the receptor, strategies using soluble decoy receptors were receptors such as "tremacamra" showed that it reduced the severity of the Monoclonal antibodies against ICAM-1 were used to inhibit the attachment of viruses to their cognate receptors. The antibody delayed the onset of HRV-induced colds in human volunteers but did not reduce the development of this receptor blocking approach is the generation of the construction of multivalent anti-ICAM-1 antibody Fab fusion proteins Detailed analysis of virus-cell interaction led to the identification of another group of inhibitory substances, i.e. capsid-binding substances. 1996) or developed over the last years, e.g. WIN-compounds such as pirodavir. However, in clinical trials, pirodavir was efficient from a promight be attributed to poor pharmacokinetics. Currently new molecules the capsid-binding substance that has been tested most extensively. It is effective against a variety of rhino-and enteroviruses, orally bioavailable and was studied in more than 5,000 patients in clinical trials. If pleconaril treatment is started early, it reduces the duration and severity of the disease Drug Administration did not approve pleconaril (Picovir™) in May 2002, mainly because of the observed induction of cytochrome P450 3A enzymes, which metabolize a variety of drugs, e.g. oral contraceptives. A new intranasal formulation of pleconaril is currently developed by Schering-Plough. Intranasal application should enable a more efficient delivery of the drug to the site of infection than the oral formulation, while limiting its systemic exposure and thereby minimizing the risk of drug interactions. Such other capsid-binding substances as BTA 798 are in the stage of early preclinical development. Enviroxime is a compound inhibiting HRV multiplication. It targets a step in the RNA replication complex that depends on the availability of the developed to block attachment (Marlin et al., 1990) . Studies with such disease though the effect was modest (Turner et al. , 1999) . with higher avidity Fang et al. , 2004) . humanized anti-ICAM antibodies with higher affinity or incidence of common cold in a clinical trial (Hayden et al. , 1988a) . A further , Several compounds were identified (Rosenwirth et al., 1995; Oren et al. disoxaril (McKinlay 1985; Andries et al., 1992; Mallamo et al., 1992) or phylactic but not from a therapeutic point of view (Hayden et al., 1995) . This related to pirodavir are being evaluated (Barnard et al., 2004) . Pleconaril is (Hayden et al., 2002 , 2003a Viropharma 2002 . However, the US Food and viral proteins 3A and 3AB (Heinz et al. , 1995; Brown-Augsburger et al. , 1999) . Similarly to 3C proteinase inhibitors, this class of compounds can be applied in tissue culture several hours after inoculation without loss of activity, as it targets a later step in the viral life cycle. Intolerance to oral dosing, poor pharmacokinetics, undesirable toxic side effects and modest benefits after intranasal administration hampered further development evaluation. Identification and molecular characterization of essential viral proteinases in HRV paved the way to the development of protease inhibitors to The two viral proteinases 2A and 3C are both essential for virus multiplication. These enzymes are involved in processing the viral polyprotein into single viral proteins. Mutations in the active sites of these proteinases lead to total inhibition of virus multiplication. Structurally, both proteases are related to trypsin-like serine proteases. Functionally, however, the active site amino acid is replaced by a cystein residue. Sequence comparisons among several HRV serotypes have demonstrated a high degree of homology among amino acid residues involved in the active site of the such other cellular cysteine proteases as caspases, they are an attractive Determination of the three-dimensional structure of the 3C protease and subsequent modeling led to the identification and development of specific activity against several HRV serotypes, HRV clinical isolates and related 2005). Importantly, AG-7088 is also effective when added in cell culture post infection, which might be an advantage compared to capsid-binding substances. Data from in vitro and phase I and II studies suggest that AG-(rupintrivir) significantly reduced total cold symptoms and was well tolerated. Prophylaxis lowered the share of subjects with positive viral cultures and viral titers. Surprisingly, it did not reduce the frequency of colds, nor did early treatment decrease the frequency of the disease though it lowered the severity of daily symptoms. As rupintrivir was not able to combat rhinoviral infection (Libby et al. , 1988; Sommergruber et al. , 1989) . target for drug discovery (Matthews et al. , 1994) . picornaviruses in vitro (Patick et al. , 1999; Kaiser et al. , 2000; Binford et al. , Hayden et al. , 2003b) . In phase II trials, a nasal spray of AG-7088 7088 is an effective and safe inhibitor of HRV replication (Hsyu et al., 2002; . AG-7088 is an irreversible peptidomimetic inhibitor with broad peptide aldehyde inhibitors (Matthews et al., 1994; Patick et al., 1999; Kaiser molecule (Seipelt et al. , 1999) . As these proteases are not closely related to Miller et al., 1985) . However, derivatives are currently under preclinical (Phillpotts et al., 1981 (Phillpotts et al., , 1983 Hayden et al., 1982; Levandowski et al., 1982; significantly effect virus reduction and moderate disease severity in subsequent natural infection studies in patients, Agouron Pharmaceuticals terminated the development. Similarly, Eli Lilly designed a compound targeting the human rhinovirus 3C protease (LY 338387) but no recent development was reported. In addition, an orally bioavailable inhibitor of HRV 3C protease was identified. A Phase I trial showed bioavailability and inhibitor for clinical use is not continued. It should be noted that 3C proteinase inhibitors are effective against a variety of HRV serotypes, as most of the amino acids critical for binding the protease inhibitor are In principle, the 2A protease of HRV is also an attractive target for therapeutic intervention. The protease activity is essential for virus multiplication; it is highly specific to its cognate cleavage site. In the life cycle, the protease is directly involved in cleaving the translation factor eIF4G, which shuts off host cell translation. So far, no specific inhibitors for the HRV 2 protease are available. Recently, we could show that the methylated form of a commonly used caspase inhibitor, zVAD.fmk, inhibits HRV2 2A protease in vitro and in cell culture, leading to an inhibition undesired side effect discovered in experiments aimed at specific inhibition caspases are usually employed as methyl-esters to facilitate cell permeation. Inside the cell endogenous esterases cause the demethylation of the inhibitors. We could show that the methylated form specifically inhibits 2A activity, whereas the de-methylated form does not. This is in good agreement care must be taken when a "specific" inhibitor is used and exemplify, that inhibition of 2A protease does indeed lead to the block of HRV multiplication. A major problem associated with common antiviral drugs targeting specific viral functions is the emergence of resistant escape mutants due to selective pressure and the high error rate in viral replication. Human rhinoviruses, as other RNA viruses, evolve as complex distributions of enzymes favours the selective advantage of some viral subpopulations over conserved . others (Vignuzzi et al. , 2005) . mutants termed viral quasispecies (Domingo et al. , 2005) . Inhibition of viral Sommergruber et al. , 1992) . However, these experiments clearly show that with substrate requirements for the 2A protease (Skern et al. , of viral multiplication (Deszcz et al. , of caspases. Fluoromethyl ketone derivatized peptides used as inhibitors of 2004). However, this is rather an lack of toxicity . Unfortunately, the development of this Although patients treated with pleconaril show a rapid decrease of viral RNA, they occasionally continued to have positive cultures on study day 6 or later, though on a low level. In a study, viruses with at least tenfold reduced susceptibility to pleconaril were found in 10% of all patients who picornaviruses with reduced susceptibility to pleconaril following exposure to the drug. In all cases examined, the molecular basis of the reduced susceptibility involved amino acid changes in the drug-binding pocket of capsid protein VP1. Similarly, resistant mutants can be found when treatment is done with rupintrivir or other anti-rhinoviral substances (Heinz To combat resistance, two main strategies are available: (i) using combinations of antiviral substances with a different mode of action to increase the selective pressure on the virus or (ii) targeting cellular rather than viral proteins. So far, several combinations of antiviral and anti-inflammatory agents were clinically tested, albeit with limited success (Gwaltney 1992 ; Sperber on our limited understanding of the complex host virus interactions. Identification of essential cellular proteins for viral multiplication and a more complete picture regarding the antiviral capabilities of host cells will allow targeting these processes for future therapeutic strategies. These compounds are moderately active in relieving nasal obstructions and rhinorrhea. Nonsteroidal anti-inflammatory drugs such as ibuprofen significantly reduce fever, sneezing and headache associated with colds decongestant combinations and other over-the-counter medicines are similar to placebo in relieving acute cough associated with upper respiratory tract For several years, zinc has been considered a possible treatment of many amongst them respiratory tract infections. Zn salts are believed to have Nikolova et al. , 2003) . infections (Smith et al. , 1993) . received this drug (Hayden et al. , 2003a) . The genotype was evaluated for et al. , 1992; Stone et al. , 1992) . Targeting cellular functions is difficult based as pseudoephedrine (Sperber et al. , 2000) and phenylpropanolamine or anticholinergic agents such as ipratropium bromide (Winther et al. , 2001) . (Winther et al. , 2001) . Antitusives, expectorants, mucolytics, antihistamineillnesses (Hill et al. , 1987; Prasad et al. , 1989 Prasad et al. , , 2002 Doerr et al. , 1997) , immunomodulatory effects and inhibit rhinovirus replication in vitro, treatment of common cold has been a subject of controversy for many years. However, a meta-analysis of studies reveals no major benefit for the public, pose the problem of its varied composition in different preparations, as it stems from a natural product. Therefore, study results are not comparable and inconclusive. However, when compared to placebo, these supplements not well-examined procedure with a soothing effect is inhalation of heated humified air. This was shown to reduce symptoms but had no influence on viral shedding (Singh 2004) . To a limited extent also prevention of rhinovirus infection was investigated experimentally. As rhinoviruses are sensitive to acid ph values, this property can be used to reduce person-to-person transmission. Disinfecting tissues with various compounds such as citric acid, malic acid and sodium lauryl sulfate have been used under experimental conditions but 1986). Amantidine is a ion channel blocker and has been used to treat and prevent influenza A for many years (1970) . It blocks the viral M2 ion channel and thus prevents acidification and uncoating of the virus. Influenza B types do not have an M protein but have an NB protein which is resistant to amantadine. In the United States, rimantidine is frequently used because of its lesser side effects. In clinical trials, amantidine reduced the duration of the disease, though side effects and the frequent emergence of resistant Based on the crystal structure of the influenza virus neuraminidase, zanamivir was developed as a specific inhibitor of this enzyme. Zanamivir is applied as inhalation and has been shown to be efficient and safe for treating influenza virus. Moreover, it is licensed for clinical use. Oseltamivir is an these results, one can conclude that benefit is lacking (Jackson et al. , 1997 , Sweet et al. , 1991 . possibly by inhibition of the viral 3C proteinase (Cordingley et al. , 1989 ) (Korant et al. , 1974; Geist et al. , 1987) . Several trials have evaluated various preparations for treating respiratory illnesses (Farr et al. , 1987) . Based on 2000; Belongia et al. , 2001) . The role of vitamin C in the prevention and except for minor subgroups (Douglas et al. , 2005) . Studies with echinacea did not show a strong benefit for the patients (Grimm et al. , 1999; Schroeder et al., 2004) . Perhaps the easiest though systematically viruses could be observed (Dolin et al., 1982; Hayden et al. , 1989 Hayden et al. , , 1991 not in natural settings (Hayden et al., 1985a; Hayden et al., 1985b; Dick et al. , orally available prodrug and is also licensed. When treatment is initiated within 48 h after infection, the duration of the disease is reduced by 1 to 2 days. Since these drugs target influenza virus only, they do not protect patients against infections caused by other viruses involved in viral respiratory infections. This means, within this limited time frame, influenza has to be correctly diagnosed versus rhinovirus and other viral respiratory infections. Further developments include the cyclopentane peramivir (BCX-1812, RWJ-270201), a highly selective inhibitor of influenza A and B virus neuraminidases and a potent inhibitor of influenza A and B virus replication mentally infected with influenza A or B viruses, oral treatment with peramivir significantly reduced nasal wash virus titers with no adverse Originally, resistant mutants against zanamivir and oseltamivir were rare. However, new results in children show the emergence of resistance in up to For a more detailed discussion of neuraminidase inhibitors see chapter 1.5. Human coronavirus infections such as 229 E were not considered serious enough to be controlled by vaccination or antiviral treatment. This view changed rapidly with the emergence of SARS, which has been associated CoV are described in chapter 3.1. Research for an efficient treatment and vaccine against RSV was of monoclonal antibody that binds to the F-protein of RSV. It consists of human (95%) and murine (5%) antibody sequences and thus has a low rate of inducing immunogenic reactions. The drug exhibits neutralizing and fusion-inhibitory activity against RSV. The protection in children is transient and has to be repeated during the RSV season. Each immunization protects a baby for about 30 days, so a new vaccination is needed each month during the respiratory syncytial virus (RSV) season. effects. Phase III clinical trials are underway (Sidwell et al. , 2002) . 18% (Kiso et al. , 2004) . limited success (Maggon et al. , 2004) . Palivizumab is a humanized IgG1 Ksiazek Peiris et al., 2003) . Therapeutic strategies against SARS-with a newly discovered coronavirus (SARS-CoV) (Drosten et al. , 2003; in cell culture (Smee et al. , 2001) . In clinical trials with patients experi- Our group has found that pyrrolidine dithiocarbamate (PDTC), a commonly used inhibitor of the transcription factor NF-κB, exerts a Interestingly, the antiviral property is not confined to the picornavirus family, as we and others have shown that PDTC is also active against borne encephalitis virus are not inhibited by PDTC. Currently, the striking property of PDTC and functionally related compounds is under investigation. We have shown so far that PDTC does not affect early steps in HRV infection such as virus attachment, internalization and uncoating. However, polyprotein processing and What is the mechanistic basis of this inhibition? PDTC is widely used as a specific inhibitor of the transcription factor NF-κB in eukaryotic cells. The molecular mechanism by which PDTC inhibits NF-κB is not yet elucidated and results obtained by different groups are contradictory. Depending on which cellular system is used, both antioxidative properties and prooxidative effects of PDTC have been described. Furthermore, inhibition of the ubiquitin-ligase system was discussed as being involved in the inhibition of NF-κB. An important question is whether the NF-κB inhibitory property of PDTC is related to its antiviral effect. Regarding this aspect, we believe that the inhibition of NF-κB is not important during rhinoviral infection. The transcription factor NF-κB is activated during picornaviral infection. However, as the viral proteinase 2A leads to a fast shut off of host cell transcription during infection, it seems unlikely that NF-κB -mediated genes have a major effect on the replication of HRVs, because the corresponding mRNAs cannot be translated. Certain NF-κB-induced genes may translate via a capindependent mechanism, though experimental evidence for this theory is lacking. We have also shown that replication of HRV in cells, in which NF-κB is constitutively inactivated by overexpression of the cellular inhibitor IκB, cannot be distinguished from controls with functional NF-κB pathways. Other inhibitors such as aspirin also fail to exert an antiviral effect against HRV. From these data we conclude that the widely known NF-κB inhibitory . replication are severely impaired when PDTC is present (Krenn et al. , 2005) . strong antiviral effect on the multiplication of human rhinovirus and poliovirus (Gaudernak et al. , 2002) . Other groups recently confirmed these results with such other picornaviruses as the coxsackievirus (Si et al. , 2005) . influenza viruses, having a very different life cycle (Grassauer et al , unpublished, Uchide et al., 2002 . However, other viruses such as tick-property of PDTC is not important for the antiviral effect in HRV. However, in influenza virus the situation might be different. Mechanistically, we have shown that metal ions such as copper and zinc is an agreement with recent reports obtained for the inhibition of coxsackievirus (van Kuppeveld F.J, pers. communication). It is tempting to speculate what the targets for metal ions in infected cells might be. In the case of rhinovirus, the proteases have been shown to be inhibited by zinc a eukaryotic cell is finely tuned, it is of major importance to analyze effects of metal ions on proteases in a cellular context. A highly interesting property of these compounds is the fact that they can inhibit both + strand RNA viruses such as HRV and -strand RNA viruses as influenza. Although the mechanistic basis for inhibition might be different in both viruses, it is an interesting question whether these substances can trigger selected pathways of an unspecific antiviral response comparable to the induction of the "antiviral state" by interferon. Elucidation of these pathways would greatly deepen our understanding of virus-host interactions and facilitate therapeutic interventions by chemical molecules. (Krenn et al. , 2005) . This ions (Cordingley et al. , 1989) . Similar results were obtained for the 3C polymerase in vitro (Hung et al. , 2002) . However, as the metal ion balance in As conventional antiviral strategies face several problems such as ineffectivity, toxicity and resistance, new approaches were taken also in the field of respiratory viruses. RNA interference (RNAi) or RNA silencing are common designations of specific posttranscriptional gene silencing (PTGS). Small interfering RNAs (siRNAs) down-regulate gene expression by binding to complementary messenger RNAs and either triggering mRNA elimination or arresting been widely employed to manipulate gene expression in diverse hosts and to identify gene function. RNAi is heavily used in basic research, and RNAibased drugs are also being developed against human diseases, tumor and metabolic disorders. Consequently, this technique is now employed to inactivate viral genes and thus block viral replication (Carmichael 2002) . siRNA molecules mediating posttranscriptional gene silencing were originally discovered in plants and caenorhabditis elegans. In plants, there is evidence that RNAi has a role in the defense against viruses, as arabidopsis strains defective in posttranscriptional gene silencing are more susceptible to 1998; Voinnet 2001) . PTGS is mediated by siRNAs that are produced by type III endoribonuclease dicer. This enzyme digests large double-stranded RNAs into 21-23 nt double-strand RNA duplexes with 2 nt 3' overhangs. Importantly, these RNAs produced by dicer can be mimicked by synthetic a multicomponent nuclease complex termed the "RNA induced silencing complex" (RISC). The antisense-strand of the siRNA duplexes serves as a guide that directs RISC to the cognate RNA, which is subsequently degraded by RNAs. This process is highly efficient, as few RNAi molecules can trigger inactivation of continuously transcribed target genes over a prolonged period of time. Thus, siRNAs are usually more efficient than short antisense RNAs. Guidelines for the choice of siRNAs are available. Preference should be given to siRNA target sequences not located in regions with heavy secondary structure such as the picornavirus IRES elements. siRNAs can be 2003; Denli et al. , 2003; Matzke et al., 2003) . This powerful technology has mRNA translation into protein (miRNA) (Plasterk 2002; Carrington et al. , virus infections (Mourrain et al. , 2000) . In addition, several plant viruses , encode proteins that counteract RNAi-mediated silencing (Brigneti et al. RNAs (Elbashir et al. , 2001) . In a second step, siRNAs are incorporated into produced (i) synthetically, (ii) by transcription from DNA templates, (iii) enzymatically by digestion of duplex RNA by cloned dicer or E. coli RNase target cells. This is achieved by the use of such synthetic carriers as cationic lipids and polymers or with the help of viral vectors. The transient nature of the siRNA-mediated silencing is not believed to be a significant limitation when targeting diseases caused by rapidly replicating viruses. This is in contrast to a more problematic situation in chronic diseases and infections by such latent or integrating viruses as HIV. Attractive targets of siRNAs are plus-strand RNA viruses, as their genome is used both as an mRNA and as a template for replication. First experiments were carried out in poliovirus. For historic reasons, the latter is frequently used as a paradigm of picornaviruses. Based on their close relationship, results with poliovirus can be translated to human rhinovirus, albeit with caution. By targeting the capsid region and the 3D polymerase, virus titer was reduced by two orders of magnitude in a one step growth inhibition occurred without need of interferon or such classical dsRNAactivated effectors as PKR and RNase L. This is in agreement with the view that RNA duplexes shorter than 30 bases do not activate the dsRNA-However, poliovirus rapidly escapes highly effective siRNAs through picornaviruses exist as a quasispecies, it seems that pre-existing mutants can be selected rapidly. Combinations of siRNAs were more successful (Gitlin et foot and mouth disease virus (FMDV), could be inhibited by siRNAs against (SARS)-associated coronavirus replication. Several siRNAs were evaluated the leader sequence inhibited the replication of SARS-CoV more strongly dependent protein kinase (Semizarov et al. , 2003) . Grubman et al. , 2005) . III (Yang et al. , 2002) . However, siRNAs have to be transported into the when cells were transfected before infection (Gitlin et al. , 2002) . Virus unique point mutations within the targeted regions (Gitlin et al. , 2005) . As al. , 2005). Another important animal virus of the picornavirus family, i.e. the siRNAs have also been used to inhibit severe acute respiratory syndrome VP1 in cell culture and suckling mice Kahana et al. , 2004; Qin et al. , 2004; Zhao et al. , 2005) . siRNAs directed against spike sequences in cell culture against different viral genes (Zhang, R. et al. , 2003 (Zhang, R. et al. , , 2004b and the 3'-UTR can inhibit replication (Bitko et al. , 2005) . siRNA targeting than targeting the spike gene (Li et al. , 2005) . Plasmid-mediated expression of siRNAs targeting the RNA polymerase reduced virus titer, RNA and The non-segmented genomic and antigenomic RNAs of RSV are a difficult target for siRNAs as they are tightly wrapped in the nucleocapsid protein N, which makes them inaccessible (Barik 2004) . However, siRNAs targeting the NS1 gene (siNS1) were successfully used in mice treated intranasally with siNS1 nanoparticles. Decreased virus titers in the lung and decreased inflammation and airway reactivity could be observed. Thus, siNS1 nanoparticles may effectively inhibit RSV infection in humans (Zhang successful in preventing infection in mice and in reducing the severity of the One of the advantages is that siRNA approaches do not rely on the immune system. Essentially, all genes of influenza were targeted by siRNAs, virus multiplication could be obtained in vitro, in chicken embryos and in mice. For example, cationic carrier siRNA complexes were administered i.v. or intranasally or via DNA vectors from which siRNAs could be transcribed virus infection in mice. Other groups used siNP nucleocapsid or siPA components to protect mice from lethal challenge with a variety of influenza A viruses including potential pandemic H5 and H7 subtypes (Tompkins et and therapy for influenza virus infections. An attractive idea is not to pursue the classical approaches of targeting the viral RNA but to target cellular genes which are identified as being essential for virus multiplication. So far, these strategies were not yet applied to classic respiratory viruses; however there are successful reports in related virus groups. Examples for such methods are targeting the translation factor La, the polypyrimidine-binding protein or eukaryotic initiation factor 2B gamma. As these factors are involved in the cap-independent translation of hepatitis C virus, siRNA targeting of these molecules blocks viral replication picornaviruses (polio-and encephalomyocaeditisvirus) when cells were These studies demonstrate that viral infections can be combated by targeting protein levels (Wang et al. , 2004 (Wang et al. , ). 2005 . Also, intranasal delivery of siRNA against RSV P was disease when added after infection (Bitko et al. , 2005) . et al. , except for hemagglutinin and neuraminidase (Ge et al. , 2003) . Inhibition of (Ge et al. , 2004a; . These siRNAs can prevent and treat influenza al. , 2004). These data clearly show the potential of siRNAs as prophylactic in cell culture (Zhang, J. et al. , 2004a) . Similar results were obtained with depleted of the polypyrimidine-tract-binding protein (Florez et al., 2005) . cellular co-factors required for replication. These approaches might lead to a more sustainable inhibition of viral replication as the emergence of resistant viruses is very unlikely. The main limit of the siRNA technology is the sequence diversity of respiratory viruses. Resistant mutants were obtained in several viruses such as poliovirus. However, siRNA is a powerful technology that can be used to target viral genes or cellular co-factors and thus efficiently inhibit virusinduced pathogenesis. Inhibiting respiratory viruses is a challenging task and many attempts have failed to show expected results. The diverse nature of the viruses involved is one reason for the problematic situation. Viruses have developed a number of strategies to evade common inhibition approaches. However, we believe that aiming at cellular rather than viral targets might improve the accessibility of viral diseases. It remains to be shown in further clinical trials whether new molecules are suitable for viral inhibition. New technologies such as siRNA techniques have yielded surprising results in the first years of development and offer a significant potential for treating viruses that have bothered people for many centuries. Amantidine and influenza in general practice In vitro activity of pirodavir (R 77975), a substituted phenoxypyridazinamine with broad-spectrum antipicornaviral activity Frequency and natural history of rhinovirus infections in adults during autumn Control of nonsegmented negative-strand RNA virus replication by siRNA In vitro activity of expanded-spectrum pyridazinyl oxime ethers related to pirodavir: novel capsid-binding inhibitors with potent antipicornavirus activity A randomized trial of zinc nasal spray for the treatment of upper respiratory illness in adults Cost burden of viral respiratory infections: issues for formulary decision makers Conservation of amino acids in human rhinovirus 3C protease correlates with broad-spectrum antiviral activity of rupintrivir, a novel human rhinovirus 3C protease inhibitor Inhibition of respiratory viruses by nasally administered siRNA Viral pathogenicity determinants are suppressors of transgene silencing in Nicotiana benthamiana Evidence that enviroxime targets multiple components of the rhinovirus 14 replication complex Medicine: silencing viruses with RNA Role of microRNAs in plant and animal development Prevention of human rhinovirus infection by multivalent fab molecules directed against ICAM-1 RNA interference targeting VP1 inhibits foot-and-mouth disease virus replication in BHK-21 cells and suckling mice Cleavage of small peptides in vitro by human rhinovirus 14 3C protease expressed in Escherichia coli Transmission of experimental rhinovirus colds in volunteer married couples Antivirals and antiviral strategies RNAi: an ever-growing puzzle Antiviral activity of caspase inhibitors: effect on picornaviral 2A proteinase Interruption of transmission of rhinovirus colds among human volunteers using virucidal paper handkerchiefs Zinc deficiency in head and neck cancer patients A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection Footand-mouth disease virus evolution: exploring pathways towards virus extinction Vitamin C for preventing and treating the common cold Identification of a novel coronavirus in patients with severe acute respiratory syndrome Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells Monoclonal antibody-aided characterization of cellular p220 in uninfected and poliovirus-infected HeLa cells: subcellular distribution and identification of conformers Viral receptor blockage by multivalent recombinant antibody fusion proteins: inhibiting human rhinovirus (HRV) infection with CFY196 Two randomized controlled trials of zinc gluconate lozenge therapy of experimentally induced rhinovirus colds Intranasal interferonalpha 2 for prevention of natural rhinovirus colds The polypyrimidine tract binding protein is required for efficient picornavirus gene expression and propagation Antiviral effects of pyrrolidine dithiocarbamate on human rhinoviruses Use of siRNAs to prevent and treat influenza virus infection Inhibition of influenza virus production in virus-infected mice by RNA interference RNA interference of influenza virus production by directly targeting mRNA for degradation and indirectly inhibiting all viral RNA transcription In vitro activity of zinc salts against human rhinoviruses Short interfering RNA confers intracellular antiviral immunity in human cells Poliovirus escape from RNA interference: short interfering RNA-target recognition and implications for therapeutic approaches Excessive antibiotic use for acute respiratory infections in the United States Respiratory consequences of rhinovirus infection The major human rhinovirus receptor is ICAM-1 A randomized controlled trial of the effect of fluid extract of Echinacea purpurea on the incidence and severity of colds and respiratory infections Rapid control of foot-and-mouth disease outbreaks: is RNAi a possible solution? Rhinovirus transmission: one if by air, two if by hand Combined antiviral and antimediator treatment of rhinovirus colds Rhinovirus infections in an industrial population. I. The occurrence of illness Hand-to-hand transmission of rhinovirus colds Rhinovirus and the lower respiratory tract Prevention of natural colds by contact prophylaxis with intranasal alpha 2-interferon Emergence and apparent transmission of rimantadine-resistant influenza A virus in families Oral pleconaril treatment of picornavirus-associated viral respiratory illness in adults: efficacy and tolerability in phase II clinical trials Prophylactic activity of intranasal enviroxime against experimentally induced rhinovirus type 39 infection Intranasal interferon-alpha 2 treatment of experimental rhinoviral colds Modification of experimental rhinovirus colds by receptor blockade Efficacy and safety of oral pleconaril for treatment of colds due to picornaviruses in adults: results of 2 double-blind, randomized, placebo-controlled trials Intranasal pirodavir (R77,975) treatment of rhinovirus colds Intranasal tolerance and histopathologic effects of a novel synthetic interferon, rIFN-alpha Con1 Recovery of drug-resistant influenza A virus during therapeutic use of rimantadine Phase II, randomized, double-blind, placebo-controlled studies of ruprintrivir nasal spray 2-percent suspension for prevention and treatment of experimentally induced rhinovirus colds in healthy volunteers Rhinovirus inactivation by nasal tissues treated with virucide The effect of placebo and virucidal paper handkerchiefs on viral contamination of the hand and transmission of experimental rhinoviral infection The common cold The antiviral compound enviroxime targets the 3A coding region of rhinovirus and poliovirus Sequence determinants of 3A-mediated resistance to enviroxime in rhinoviruses and enteroviruses Treatment of Wilson's disease with zinc. I. Oral zinc therapy regimens Members of the low density lipoprotein receptor family mediate cell entry of a minor-Group common cold virus Pharmacokinetics and safety of an antirhinoviral agent, ruprintrivir, in healthy volunteers Biochemical characterization of rhinovirus RNA-dependent RNA polymerase Virus interference. I. The interferon Virus interference. II. Some properties of interferon Zinc and the common cold: a meta-analysis revisited A meta-analysis of zinc salts lozenges and the common cold Inhibition of foot-and-mouth disease virus replication by small interfering RNA In vitro activity of pleconaril and AG7088 against selected serotypes and clinical isolates of human rhinoviruses Respiratory syncytial virus detection by immunofluorescence in nasal secretions with monoclonal antibodies against selected surface and internal proteins Resistant influenza A viruses in children treated with oseltamivir: descriptive study Zinc ions inhibit replication of rhinoviruses The inhibition of polyprotein processing and RNA replication of Human Rhinovirus by PDTC depends on metal ions A novel coronavirus associated with severe acute respiratory syndrome Isolation of rhinoviruses and coronaviruses from 38 colds in adults Topical enviroxime against rhinovirus infection siRNA targeting the leader sequence of SARS-CoV inhibits virus replication Human Rhinovirus 3C Protease: Cloning and Expression of an Active Form in Escherichia coli Studies on the production, mode of action and properties of interferon Characterization of viral agents causing acute respiratory infection in a San Francisco University Medical Center Clinic during the influenza season Humanization of an anti-ICAM-1 antibody with over 50-fold affinity and functional improvement New drugs and treatment for respiratory syncytial virus Viruses and bacteria in the etiology of the common cold Conformationally restricted analogues of disoxaril: a comparison of the activity against human rhinovirus types 14 and 1A A soluble form of intercellular adhesion molecule-1 inhibits rhinovirus infection Structure of human rhinovirus 3C protease reveals a trypsin-like polypeptide fold, RNA-Binding site, and means for cleaving precursor polyprotein RNAi extends its reach WIN 51711, a new systematically active broad-spectrum antipicornavirus agent Controlled trial of enviroxime against natural rhinovirus infections in a community Epidemiology of viral respiratory infections The seasonality of rhinovirus infections and its implications for clinical recognition Acute respiratory illness in the community. Frequency of illness and the agents involved Similar frequency of rhinovirus-infectible cells in upper and lower airway epithelium Quantitative and qualitative analysis of rhinovirus infection in bronchial tissues Arabidopsis SGS2 and SGS3 genes are required for posttranscriptional gene silencing and natural virus resistance Acute viral infections of upper respiratory tract in elderly people living in the community: comparative, prospective, population based study of disease burden One-incubation time-resolved fluoroimmunoassay based on monoclonal antibodies in detection of influenza A and B viruses directly in clinical specimens Development of resistance to disoxaril in Coxsackie B1 virus-infected newborn mice Synthesis and activity of piperazine-containing antirhinoviral agents and crystal structure of SDZ 880-061 bound to human rhinovirus 14 Rhinoviruses replicate effectively at lower airway temperatures In vitro antiviral activity of AG7088, a potent inhibitor of human rhinovirus 3C protease In vitro antiviral activity and single-dose pharmacokinetics in humans of a novel, orally bioavailable inhibitor of human rhinovirus 3C protease Coronavirus as a possible cause of severe acute respiratory syndrome The activity of enviroxime against rhinovirus infection in man Therapeutic activity of enviroxime against rhinovirus infection in volunteers Detection of rhinovirus in sinus brushings of patients with acute community-acquired sinusitis by reverse transcription-PCR Respiratory viruses and acute otitis media Rhinovirus RNA in children with longstanding otitis media with effusion Detection of rhinovirus, respiratory syncytial virus, and coronavirus infections in acute otitis media by reverse transcriptase polymerase chain reaction RNA silencing: the genome s immune system Immunological effects of zinc deficiency in sickle cell anemia Zinc in cancer prevention Silencing of SARS-CoV spike gene by small interfering RNA in HEK 293T cells SDZ 35-682, a new picornavirus capsid-binding agent with potent antiviral activity Over-the-counter medications for acute cough in children and adults in ambulatory settings The structures of picornaviral proteinases Specificity of short interfering RNA determined through gene expression signatures Pyrrolidine dithiocarbamate reduces coxsackievirus B3 replication through inhibition of the ubiquitin-proteasome pathway Peramivir, BCX-1812 (RWJ-270201): potential new therapy for influenza Heated, humidified air for the common cold Substrate requirements of a human rhinoviral 2A proteinase Cyclopentane neuraminidase inhibitors with potent in vitro anti-influenza virus activities Over-the-Counter cold medications -a critical review of clinical trials between Cleavage specifity on synthetic peptide substrates of human rhinovirus 2 proteinase 2A Polypeptide 2A of human rhinovirus type 2: identification as a protease and characterization by mutational analysis Effects of naproxen on experimental rhinovirus colds. A randomized, doubleblind, controlled trial Ineffectiveness of recombinant interferon-beta serine nasal drops for prophylaxis of natural colds Effectiveness of pseudoephedrine plus acetaminophen for treatment of symptoms attributed to the paranasal sinuses associated with the common cold Early detection of acute rhinovirus infections by a rapid reverse transcription-PCR assay Effectiveness of reverse transcription-PCR, virus isolation, and enzyme-linked immunosorbent assay for diagnosis of influenza A virus infection in different age groups Human major group rhinoviruses downmodulate the accessory function of monocytes by inducing IL-10 Development of common cold symptoms following experimental rhinovirus infection is related to prior stressful life events Virulence of rimantadine-resistant human influenza A (H3N2) viruses in ferrets Protection against lethal influenza virus challenge by RNA interference in vivo Prevention of experimental coronavirus colds with intranasal alpha-2b interferon Ineffectiveness of echinacea for prevention of experimental rhinovirus colds Efficacy of tremacamra, a soluble intercellular adhesion molecule 1, for experimental rhinovirus infection: a randomized clinical trial Inhibition of influenza-virusinduced apoptosis in chorion cells of human fetal membranes by nordihydroguaiaretic Acid Effect of antioxidants on apoptosis induced by influenza virus infection: inhibition of viral gene replication and transcription with pyrrolidine dithiocarbamate An outbreak of coronavirus OC43 respiratory infection in Normandy, France Ribavirin and lethal mutagenesis of poliovirus: molecular mechanisms, resistance and biological implications Antiviral Drugs Advisory Committee Briefing Document (PICOVIR, PLECONARIL) NDA 21-245 Human rhinovirus type 89 variants use heparan sulfate proteoglycan for cell attachment RNA silencing as a plant immune system against viruses Inhibition of severe acute respiratory syndrome virus replication by small interfering RNAs in mammalian cells Time-resolved fluoroimmunoassay compared with virus isolation for rapid detection of respiratory syncytial virus in nasopharyngeal aspirates Inverse interference: how viruses fight the interferon system The therapeutic effectiveness of ibuprofen on the symptoms of naturally acquired common colds Short RNA duplexes produced by hydrolysis with Escherichia coli RNase III mediate effective RNA interference in mammalian cells Down-regulation of viral replication by adenoviralmediated expression of siRNA against cellular cofactors for hepatitis C virus Inhibiting severe acute respiratory syndrome-associated coronavirus by small interfering RNA Inhibition of respiratory syncytial virus infection with intranasal siRNA nanoparticles targeting the viral NS1 gene Silencing SARS-CoV Spike protein expression in cultured cells by RNA interference Small interfering RNA inhibits SARS-CoV nucleocapsid gene expression in cultured cells and mouse muscles Interferon action in triply deficient mice reveals the existence of alternative antiviral pathways This chapter is dedicated to the memory of our head and mentor Ernst Kuechler who was substantially involved in the research presented in this chapter. Sadly, Ernst Kuechler passed away in March 2005. We would like to thank Sylvia Trnka for editorial help and acknowledge support by grant P16642-B11 from the Austrian Science Foundation.